Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial

W. J. Sandborn, B. E. Sands, D. C. Wolf, J. F. Valentine, M. Safdi, S. Katz, K. L. Isaacs, L. D. Wruble, J. Katz, D. H. Present, E. V. Loftus, F. Graeme-Cook, D. J. Odenheimer, S. B. Hanauer

Research output: Contribution to journal › Article › peer-review

90 Scopus citations

Fingerprint

Dive into the research topics of 'Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial'. Together they form a unique fingerprint.

Medicine & Life Sciences